Holen Sie sich die Stockscreener-App
19.23
6.30%
1.14
Handel nachbörslich:
19.00
-0.23
-1.20%
Schlusskurs vom Vortag:
$18.09
Offen:
$18.29
24-Stunden-Volumen:
5.25M
Relative Volume:
1.41
Marktkapitalisierung:
$14.28B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-60.09
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
+3.39%
1M Leistung:
-26.85%
6M Leistung:
-3.03%
1J Leistung:
-21.70%
1-Tages-Spanne:
$18.18
$19.29
1-Wochen-Bereich:
$17.76
$19.97
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.23 | 13.44B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Summit Therapeutics spikes after co-CEO’s early warrants exercise - MSN
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - Insider Monkey
Aug Sectors: What’s next for Summit Therapeutics Inc. stockJuly 2025 Big Picture & Real-Time Buy Signal Notifications - خودرو بانک
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat
Using Bollinger Bands to evaluate Summit Therapeutics Inc.July 2025 Summary & Daily Stock Momentum Reports - newser.com
Investment Review: Is Summit Therapeutics Inc benefiting from innovation trendsWeekly Loss Report & Fast Momentum Entry Tips - خودرو بانک
Is now a turning point for Summit Therapeutics Inc.Portfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential - FXEmpire
Tools to assess Summit Therapeutics Inc.’s risk profileJuly 2025 Gainers & Safe Entry Trade Signal Reports - newser.com
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Summit Therapeutics (NASDAQ:SMMT) Receives Buy Rating from HC Wainwright - MarketBeat
Summit Therapeutics (SMMT) Receives "Underweight" Rating from Ba - GuruFocus
Barclays Initiates Coverage of Summit Therapeutics (SMMT) with Underweight Recommendation - Nasdaq
Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target - MarketScreener
Short interest data insights for Summit Therapeutics Inc.2025 Dividend Review & Community Shared Stock Ideas - newser.com
Will Summit Therapeutics Inc. bounce back from current supportWeekly Risk Report & Free Verified High Yield Trade Plans - newser.com
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Focus Partners Wealth Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Insider Buying Activity - MarketBeat
695,000 Shares in Summit Therapeutics PLC $SMMT Acquired by Siren L.L.C. - MarketBeat
Aug EndMonth: Does Summit Therapeutics Inc. meet Warren Buffett’s criteriaNew Guidance & Safe Entry Momentum Stock Tips - خودرو بانک
Summit Therapeutics (NASDAQ:SMMT) CEO Robert W. Duggan Acquires 333,394 Shares - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 333,394 Shares - MarketBeat
Fed Meeting: What is Summit Therapeutics Inc. s revenue forecastJuly 2025 Action & Accurate Buy Signal Alerts - خودرو بانک
SMMT: HC Wainwright & Co. Reiterates Buy Rating at $50.00 | SMMT Stock News - GuruFocus
Is a relief rally coming for Summit Therapeutics Inc. holdersMarket Performance Summary & AI Enhanced Trade Execution Alerts - newser.com
Sectors Review: What’s next for Summit Therapeutics Inc. stockAnalyst Downgrade & Stepwise Trade Signal Guides - خودرو بانک
Sectors Review: Can Summit Therapeutics Inc beat the S P 500Dollar Strength & Advanced Swing Trade Entry Alerts - خودرو بانک
Real time alert setup for Summit Therapeutics Inc. performanceWeekly Risk Summary & Precise Buy Zone Tips - newser.com
Shorts Report: Can Summit Therapeutics Inc stock outperform in a bear marketInsider Buying & Expert Approved Momentum Ideas - خودرو بانک
Trend Recap: Can Summit Therapeutics Inc be the next market leaderMarket Risk Report & High Accuracy Trade Alerts - خودرو بانک
Update Recap: What are Summit Therapeutics Inc.’s recent SEC filings showingIPO Watch & Stepwise Trade Execution Plans - خودرو بانک
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How to use Fibonacci retracement on Summit Therapeutics Inc.July 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Jim Cramer: Ring The Register On This Real Estate 'Meme' Stock - Benzinga
Will Summit Therapeutics Inc. benefit from macro trendsWeekly Trading Summary & Community Verified Trade Signals - newser.com
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.2%Should You Sell? - MarketBeat
How institutional ownership impacts Summit Therapeutics Inc. stockPortfolio Profit Report & High Yield Equity Trading Tips - newser.com
Tick level data insight on Summit Therapeutics Inc. volatilityRecession Risk & Weekly High Potential Stock Alerts - newser.com
Is Summit Therapeutics Inc. reversing from oversold territory2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Summit Therapeutics Inc. stock chart pattern explainedRate Hike & AI Powered Buy and Sell Recommendations - newser.com
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Summit Therapeutics' (SMMT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Summit Therapeutics' (SMMT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Adage Capital Partners GP L.L.C. Takes Position in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) Shares Surge After CEO Stock Purchases - GuruFocus
Summit Therapeutics Stock (SMMT) Opinions on HARMONi Trial Data Release - Quiver Quantitative
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.25%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):